Published in Clin Cancer Res on September 15, 2008
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 2.00
The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res (2008) 1.62
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol (2009) 1.43
Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations. PLoS One (2015) 1.42
Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res (2010) 1.34
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther (2009) 1.29
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer (2010) 1.25
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol (2011) 1.24
Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One (2010) 1.19
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Hypoxia potentiates glioma-mediated immunosuppression. PLoS One (2011) 1.17
Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res (2010) 1.15
The role of JAK-STAT signaling within the CNS. JAKSTAT (2013) 1.12
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol (2010) 1.10
Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res (2009) 1.10
Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res (2010) 1.09
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother (2008) 1.06
Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol (2012) 1.02
Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther (2010) 1.02
Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics (2009) 1.00
The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am (2010) 0.98
Immune therapeutic targeting of glioma cancer stem cells. Target Oncol (2010) 0.95
Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol (2010) 0.95
Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One (2014) 0.95
Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med (2014) 0.87
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget (2015) 0.85
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer (2011) 0.83
Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm (2013) 0.83
Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res (2015) 0.83
Central role of cellular senescence in TSLP-induced airway remodeling in asthma. PLoS One (2013) 0.82
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J Pharmacol Exp Ther (2014) 0.82
Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget (2016) 0.82
Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep (2016) 0.82
The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget (2012) 0.81
Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin Dev Immunol (2013) 0.81
yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med (2009) 0.79
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). Bioorg Med Chem (2014) 0.78
A STATement on vemurafenib-resistant melanoma. J Invest Dermatol (2013) 0.77
JAK/STAT regulation of Aspergillus fumigatus corneal infections and IL-6/23-stimulated neutrophil, IL-17, elastase, and MMP9 activity. J Leukoc Biol (2016) 0.76
The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies. Surg Neurol Int (2011) 0.76
Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization. Cancer Med (2015) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg (2014) 0.75
WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3. Cancer Sci (2016) 0.75
Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model. Cancer Biol Ther (2014) 0.75
Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice. Lung (2015) 0.75
IL-7 receptor blockade inhibits IL-17-producing γδ cells and suppresses melanoma development. Inflammation (2014) 0.75
Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug. Mol Cell Biochem (2017) 0.75
Mechanisms of autophagy and apoptosis mediated by JAK2 signaling pathway after spinal cord injury of rats. Exp Ther Med (2017) 0.75
A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. PLoS One (2017) 0.75
Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem (2007) 10.41
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
A family of cytokine-inducible inhibitors of signalling. Nature (1997) 9.22
SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol (2007) 6.89
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene (2004) 2.82
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene (2006) 2.37
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res (2005) 2.19
Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res (2007) 2.06
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res (2006) 1.97
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res (2007) 1.91
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med (2006) 1.84
Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol (2006) 1.70
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia. J Immunol (2007) 1.58
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res (2007) 1.49
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol (2007) 1.35
Stat3 as a potential target for cancer immunotherapy. J Immunother (2007) 1.24
Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery (2002) 1.23
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function. Eur J Immunol (2007) 1.20
Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer (2001) 1.01
Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer (2006) 0.97
The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma. Br J Plast Surg (2002) 0.79
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab (2011) 3.54
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet (2011) 3.02
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
A comparative study of limited-angle cone-beam reconstruction methods for breast tomosynthesis. Med Phys (2006) 2.94
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res (2004) 2.88
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Impact of PhD training on scholarship in a neurosurgical career. J Neurosurg (2013) 2.59
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
ZINBA integrates local covariates with DNA-seq data to identify broad and narrow regions of enrichment, even within amplified genomic regions. Genome Biol (2011) 2.47
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res (2009) 2.38
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet (2011) 2.26
Retracted Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res (2010) 2.24
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell (2012) 2.20
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet (2011) 2.13
Proteomic and immunologic analyses of brain tumor exosomes. FASEB J (2008) 2.11
Risk Factors Associated with Left-Sided Cardiac Valve Calcification: A Case Control Study. Cardiology (2016) 2.04
Mkks-null mice have a phenotype resembling Bardet-Biedl syndrome. Hum Mol Genet (2005) 2.04
Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol (2012) 2.02
Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest (2004) 2.02
Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest (2006) 2.02
Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis (2008) 2.01
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 2.00
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Multiaxial mechanical behavior of biological materials. Annu Rev Biomed Eng (2003) 1.99
Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res (2003) 1.96
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res (2007) 1.91
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res (2003) 1.85
Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol (2015) 1.85
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83
Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev (2009) 1.82
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol (2011) 1.82
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress. ACS Nano (2011) 1.78
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Single-molecule approach to bacterial genomic comparisons via optical mapping. J Bacteriol (2004) 1.76
Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics (2002) 1.75
The effects of cardiopulmonary bypass on the number of cerebral microemboli and the incidence of cognitive dysfunction after coronary artery bypass graft surgery. Anesth Analg (2009) 1.74
seeQTL: a searchable database for human eQTLs. Bioinformatics (2011) 1.72
Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol (2009) 1.71
Synthesis, characterization and DNA-binding properties of a new cobalt(II) complex: Co(bbt)2Cl2. J Inorg Biochem (2005) 1.70
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol (2002) 1.69
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol (2009) 1.68
Salicylate induced tinnitus: behavioral measures and neural activity in auditory cortex of awake rats. Hear Res (2006) 1.67
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther (2009) 1.67
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res (2007) 1.67
Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan. Geriatr Gerontol Int (2013) 1.67
Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol (2007) 1.66
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2009) 1.65
Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol (2011) 1.65
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res (2011) 1.64